Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has approved Baqsimi (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages ...

Eli Lilly announced Monday morning that it is divesting Baqsimi, its low blood sugar rescue treatment, to Amphastar Pharmaceuticals for $500 million. The boards of directors at both companies have ...

The Food and Drug Administration (FDA) has approved Baqsimi (glucagon; Eli Lilly) nasal powder for the treatment of severe hypoglycemia in patients with diabetes aged 4 years and older. The Food and ...

July 24 (Reuters) - The U.S. Food and Drug Administration approved Eli Lilly and Co's treatment for severe hypoglycemia, the health regulator said on Wednesday. Hypoglycemia is a condition in which ...

FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured in Branchburg, New Jersey (Reuters) -Amphastar Pharmaceuticals will buy Baqsimi from Eli Lilly and Co in a deal ...

Eli Lilly and Co. plans to sell its drug to treat low blood sugar to California-based Amphastar Pharmaceuticals in a deal that could be worth up to $1.1 billion. The two companies said they have ...

School personnel should soon be allowed to administer a new nasal spray used to treat severe hypoglycemia. In 2019, the Food and Drug Administration approved the use of Baqsimi nasal powder, the first ...

The US Food and Drug Administration (FDA) has approved the first nasally administered glucagon product (Baqsimi, Eli Lilly and Co) for the treatment of severe hypoglycemia for patients aged 4 years or ...

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an ...

The European Medicines Agency (EMA) Committee for Medicinal Products (CHMP) has recommended approval of the first nasal glucagon product (Baqsimi, Eli Lilly Nederland BV) for treatment of severe ...

Changes in net revenues as compared to the first quarter of the prior year were primarily driven by: BAQSIMI ® sales increased primarily due to an increase in unit volume, as we assumed full ...

July 24 (Reuters) - The U.S. Food and Drug Administration approved Eli Lilly and Co's treatment for severe hypoglycemia, the health regulator said on Wednesday. Hypoglycemia is a condition in which ...